Pulmonary non-tuberculous mycobacterial infections

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 6, 2010, Pages 665-671

  Daley, Charles D ^a,b   Griffith, D E ^c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TEXAS AT TYLER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; ISONIAZID; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TIGECYCLINE;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRONCHIECTASIS; BRONCHUS BIOPSY; CHEMOTHERAPY; DISEASE COURSE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; GROWTH RATE; HEMOPTYSIS; HUMAN; INFECTION RATE; LUNG BIOPSY; LUNG INFECTION; LUNG SURGERY; LUNG TUBERCULOSIS; MORBIDITY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ALVEI; MYCOBACTERIUM ARUPENSE; MYCOBACTERIUM ASIATICUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOENICKEI; MYCOBACTERIUM BOLLETTII; MYCOBACTERIUM BRANDERI; MYCOBACTERIUM BRUMAE; MYCOBACTERIUM CELATUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM CHIMAERA; MYCOBACTERIUM CONFLUENTIS; MYCOBACTERIUM ELEPHANTIS; MYCOBACTERIUM FLORENTINUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM GOODII; MYCOBACTERIUM HECKESHORNENSE; MYCOBACTERIUM HOLSATICUM; MYCOBACTERIUM INTERJECTUM; MYCOBACTERIUM INTERMEDIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM KUBICAE; MYCOBACTERIUM LENTIFLAVUM; MYCOBACTERIUM MAGERITENSE; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM MASSILIENSE; MYCOBACTERIUM MUCOGENICUM; MYCOBACTERIUM PALUSTRE; MYCOBACTERIUM PEREGRINUM; MYCOBACTERIUM PHOCAICUM; MYCOBACTERIUM SASKATCHEWANSE; MYCOBACTERIUM SCROFULACEUM; MYCOBACTERIUM SEPTICUM; MYCOBACTERIUM SHIMODEI; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM THERMORESISTIBLE; MYCOBACTERIUM TRIPLEX; MYCOBACTERIUM XENOPEI; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SPECIES DIFFERENCE; SPECIES RICHNESS; SPUTUM CULTURE; TRACHEOBRONCHIAL TOILET; TREATMENT INDICATION; DIFFERENTIAL DIAGNOSIS; HEALTH; INCIDENCE; ISOLATION AND PURIFICATION; LUNG DISEASES; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PREVALENCE;

DIAGNOSIS, DIFFERENTIAL; GLOBAL HEALTH; HUMANS; INCIDENCE; LUNG DISEASES; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PREVALENCE;

EID: 77952374187     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
2. Marras T K, Daley C L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-567.
3. Marras T K, Chedore P, Ying A M, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario 1997-2003. Thorax 2007; 8: 661-666.
4. van Ingen J, Bendien S A, de Lange W C, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009; 64: 502-506.
5. Andrejak C, Thomsen V O, Johansen I S, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-521.
6. Lai C C, Tan C K, Chou C H, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 2010; 16: 294-296.
7. Butler W, Crawford J, Shutt K. Nontuberculous mycobacteria reported to the Public Health Laboratory Information System by state public health laboratories, United States, 1993-1996. Atlanta, GA, USA: Centers for Disease Control and Prevention, 1999.
8. Iseman M D, Marras T K. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2008; 178: 999-1000.
9. Billinger M E, Olivier K N, Viboud C, et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis 2009; 15: 1562-1569.
10. Cassidy P M, Hedberg K, Saulson A, McNelly E, Winthrop K L. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49: e124-129.
11. Dailloux M, Abalain M L, Laurain C, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006; 28: 1211-1215. (Pubitemid 44883858)
12. Khan K, Wang J, Marras T K. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176: 306-313. (Pubitemid 47195882)
13. Tsukamura M. Diagnosis of disease caused by Mycobacterium avium complex. Chest 1991; 99: 667-669.
14. Wallace R J Jr, Brown A, Griffith D E. Nosocomial outbreaks/pseudo- outbreaks caused by nontuberculous mycobacteria. Ann Rev Microbiol 1998; 52: 453-490.
15. Park S, Suh G Y, Chung M P, et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008; 102: 437-442.
16. Hoefsloot W, van Ingen J, de Lange W C, Dekhuijzen P N, Boeree M J, van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009; 34: 926-931.
17. van Ingen J, Boeree M J, de Lange W C, de Haas P E, Dekhuijzen P N, van Soolingen D. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008; 46: 1200-1205.
18. van Ingen J, de Zwaan R, Dekhuijzen R P, Boeree M J, van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009; 59: 324-331.
19. Koh W J, Kwon O J, Jeon K, et al. Clinical signifi cance of non-tuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129: 341-348. (Pubitemid 43289853)
20. Griffith D E, Brown-Elliott B A, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174: 928-934.
21. Jenkins P A, Campbell I A, Banks J, Gelder C M, Prescott R J, Smith A P. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63: 627-634. (Pubitemid 351969257)
22. Shitrit D, Baum G L, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129: 771-776.
23. Griffith D E, Brown-Elliot B A, Wallace R J Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37: 1178-1182.
24. Wallace R J Jr, Dunbar D F, Brown B A, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994; 18: 1736-1743.
25. Hoefsloot W, Boeree M J, van Ingen J, et al. The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis 2008; 12: 987-993.
26. van Ingen J, Boeree M J, de Lange W C, et al. Mycobacterium xenopi clinical relevance and determinants, The Netherlands. Emerg Infect Dis 2008; 14: 385-389.
27. Andrejak C, Lescure F X, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64: 291-296.
28. Griffith D E, Girard W M, Wallace R J Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-1278.
29. Nash K A, Brown-Elliott B A, Wallace R J Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376.
30. Ntziora F, Falagas M E. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 2007; 11: 606-611. (Pubitemid 46868619)
31. Jeon K, Kwon O J, Lee N Y, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180: 896-902.
32. Wallace R J Jr, Brown B A, Onyi G O. Skin, soft tissue, and bone infections due to Mycobacterium chelonae: importance of prior corticosteroid therapy, frequency of disseminated i nfections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1982; 166: 405-412.
33. Brown B A, Wallace R J Jr, Onyi G O, De Rosa V, Wallace R J III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-184.
34. Nash K A, Zhang Y, Brown-Elliot B A, Wallace R J Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55: 170-177.
35. Mitchell J D, Bishop A, Cafaro A, Weyant M J, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85: 1887-1192; discussion 92-93. (Pubitemid 351685593)